United Action for Allergy and Asthma – a European political Call to Action
April 25th 2017, marked the launch of the political Call to Action - ‘United Action for Allergy and Asthma' at the European Parliament in Brussels.
This campaign has been initiated by the European Academy of Allergy and Clinical Immunology (EAACI) and the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), in partnership with the European Parliament Interest Group on Allergy and Asthma.
Our mission: Improved quality of life for allergy and asthma patients
The objective is to unite all strategic parties and interested individuals in Europe to help drive change in the policy responses to allergy and asthma. Through a successful campaign, the relevant EU and national healthcare bodies will be supported in further developing and improving a collaborative and holistic approach for high quality patient care in the future.
or specialised in the field or, of course, a policy maker.
|The first step of the campaign is to collect signatures to show the need for development in monitoring, preventing and treating allergies and asthma. This can be done until 30th September 2017.||
Step two will take the signed endorsement list and the official Call to Action document to decision-making European institutions. The need for development and specific policy asks of EU Member States, European Commission, European Parliament will be presented for discussion. Following successful discussions, definitive action plans for implementation will be created.
By signing this campaign, you are supporting the development of the following points:
Public health – implementing European strategies and programmes across Member States
Funding for research – advancing our understanding of allergy and asthma
Prevention and early diagnosis – achieving early detection for timely and effective treatment
Root cause analysis of diseases – addressing underlying triggers such as air quality, food allergens, chemicals
Personalised medicine - working towards pioneering individualised treatment
Economic benefit – reducing direct and indirect costs on health systems and society